Your browser doesn't support javascript.
loading
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde, Lihua E; Assouline, Sarit; Sehn, Laurie H; Schuster, Stephen J; Yoon, Sung-Soo; Yoon, Dok Hyun; Matasar, Matthew J; Bosch, Francesc; Kim, Won Seog; Nastoupil, Loretta J; Flinn, Ian W; Shadman, Mazyar; Diefenbach, Catherine; O'Hear, Carol; Huang, Huang; Kwan, Antonia; Li, Chi-Chung; Piccione, Emily C; Wei, Michael C; Yin, Shen; Bartlett, Nancy L.
Afiliación
  • Budde LE; City of Hope National Medical Center, Duarte, CA.
  • Assouline S; Jewish General Hospital and McGill University, Montreal, Quebec, Canada.
  • Sehn LH; BC Cancer Centre for Lymphoid Cancer and The University of British Columbia, Vancouver, British Columbia, Canada.
  • Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Yoon SS; Seoul National University Hospital, Seoul, South Korea.
  • Yoon DH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Matasar MJ; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Bosch F; University Hospital Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Kim WS; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
  • Nastoupil LJ; MD Anderson Cancer Center, Houston, TX.
  • Flinn IW; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
  • Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Diefenbach C; Perlmutter Cancer Center at NYU Langone Health, New York, NY.
  • O'Hear C; Genentech, Inc, South San Francisco, CA.
  • Huang H; F. Hoffmann-La Roche Limited, Mississauga, Ontario, Canada.
  • Kwan A; Genentech, Inc, South San Francisco, CA.
  • Li CC; Genentech, Inc, South San Francisco, CA.
  • Piccione EC; Genentech, Inc, South San Francisco, CA.
  • Wei MC; Genentech, Inc, South San Francisco, CA.
  • Yin S; Genentech, Inc, South San Francisco, CA.
  • Bartlett NL; Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
J Clin Oncol ; 40(5): 481-491, 2022 02 10.
Article en En | MEDLINE | ID: mdl-34914545
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B / Anticuerpos Biespecíficos / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfoma de Células B / Anticuerpos Biespecíficos / Antineoplásicos Inmunológicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Canadá